SNPX
Synaptogenix, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ynaptogen.com
- Employees(FY) 5
- ISIN US87167T3005
Performance
+0.85%
1W
+2.15%
1M
+6.2%
3M
-19.29%
6M
-30.12%
YTD
-76.83%
1Y
Profile
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.
Technical Analysis of SNPX 2024-05-10
Overview:
In analyzing the technical indicators for SNPX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potential inv...
Recent News & Updates
- 2024-05-06 21:00
- 2024-04-23 21:15
- 2024-04-08 21:15
- 2024-04-02 20:00
- 2023-12-18 20:00
- 2023-12-05 20:00
- 2023-11-01 21:00
- 2023-09-25 21:00
- 2023-09-06 21:00
- 2023-07-18 21:00
- 2023-07-12 21:00
- 2023-03-06 20:00
- 2022-12-15 20:00
- 2022-11-17 20:00
- 2022-10-18 21:00
- 2022-09-27 23:50
Synaptogenix Welcomes Lecanemab Phase 3 Trial Results(Yahoo Finance)
- 2022-08-11 21:00
- 2022-07-25 21:15
- 2022-07-20 21:15
Synaptogenix Announces Corporate Update Conference Call(Yahoo Finance)
- 2022-07-19 21:15
- 2022-05-16 21:15
Synaptogenix to Present at the Cell Symposium(Yahoo Finance)
- 2022-04-18 21:15
- 2022-04-04 21:15
- 2022-03-28 21:15
- 2022-03-21 21:15
- 2022-03-14 21:15
- 2022-02-22 20:15
- 2022-02-06 20:38
- 2022-01-31 20:15
- 2021-12-05 22:58
Page 1 of 2
previousnext